Shu-Hong Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shu-Hong Lin has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Mitchell J. Machiela
National Cancer Institute
18 shared publications - Derek W. Brown
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA
16 shared publications - Stephen J. Chanock
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health , Bethesda, MD
11 shared publications - Alexander DePaulis
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland
10 shared publications - Aubrey K. Hubbard
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, USA
10 shared publications - Batel Blechter
Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD
10 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Adjusted association between incident CLL and chromosome-specific mCAs by 5 Mb bin within UKBB. Analyses are adjusted for age, age-squared, smoking status (N/F/C), and genetic similarity. Detailed results are given in Supplemental Table 6.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Adjusted association between incident CLL and chromosome-specific mCAs by 5 Mb bin within UKBB. Analyses are adjusted for age, age-squared, smoking status (N/F/C), and genetic similarity. Detailed results are given in Supplemental Table 6.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1-22 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Supplemental Tables1-22 display descriptive characteristics for both studies and the results of all analyses.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1-22 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Supplemental Tables1-22 display descriptive characteristics for both studies and the results of all analyses.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Overlayed density plots for sensitivity analysis removing individuals with total white blood cell count (WBC) above 9.57 × 109 cells/L for absolute risk prediction models of developing CLL for ages 40-80 in UKBB testing set. Models sequentially add demographics, blood cell traits, CLL PGS, and CH to each model. Median and mean of model distributions are in Supplemental Table 21.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Overlayed density plots for sensitivity analysis removing individuals with total white blood cell count (WBC) above 9.57 × 109 cells/L for absolute risk prediction models of developing CLL for ages 40-80 in UKBB testing set. Models sequentially add demographics, blood cell traits, CLL PGS, and CH to each model. Median and mean of model distributions are in Supplemental Table 21.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Model calibration on the 30% UK Biobank testing (validation) set. Calibration was performed on absolute risk final model including all variables and using the built-in calibration from iCARE on a relative risk scale. The observed relative risk in each risk decile is defined as the ratio of the observed proportion of cases in that category and the observed proportion of cases in the validation study (testing set). For comparison, the predicted relative risk is computed as the average of the predicted absolute risk over the subjects in that category and the overall average of the predicted absolute risks in the validation study.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Model calibration on the 30% UK Biobank testing (validation) set. Calibration was performed on absolute risk final model including all variables and using the built-in calibration from iCARE on a relative risk scale. The observed relative risk in each risk decile is defined as the ratio of the observed proportion of cases in that category and the observed proportion of cases in the validation study (testing set). For comparison, the predicted relative risk is computed as the average of the predicted absolute risk over the subjects in that category and the overall average of the predicted absolute risks in the validation study.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Sensitivity analysis using binary disease status to visualize ROC Curves based on 10-year risk prediction. Results are based on 90/10 testing to training set in UK Biobank.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Sensitivity analysis using binary disease status to visualize ROC Curves based on 10-year risk prediction. Results are based on 90/10 testing to training set in UK Biobank.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Both acquired mutations and germline genetic variation are known risk factors for chronic lymphocytic leukemia (CLL). The joint characterization of germline, acquired, and clinical risk has the potential to improve CLL risk prediction. In this study, we investigated whether the inclusion of a CLL-associated polygenic score (PGS) and two common types of clonal hematopoiesis (CH), autosomal mosaic chromosomal alterations (mCA) and CH of indeterminate potential (CHIP), could improve CLL risk stratification in 436,784 participants in the UK Biobank and a replication set of 35,382 participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Individual mCAs on chromosomes 11, 12, 23, 14, and 22, as well as CHIP mutations in known lymphoid driver genes, were strongly associated with CLL risk. Integrative models that included sex, age, smoking status, blood cell traits, genetic similarity, CLL PGS, autosomal mCAs, and CHIP had the greatest discriminative ability, with predictive utility waning 5 years after the measurement of CH. Sensitivity analyses removing individuals with abnormal blood cell counts and CH commonly observed in CLL showed persistent, increased discriminative ability. Evaluating cumulative absolute risk, the CLL PGS and CH had improved ability to stratify CLL cases into higher-risk categories and controls into lower-risk categories. Overall, this analysis details the enhanced ability to identify individuals at high risk of CLL when integrating germline and somatic data derived from peripheral blood.Significance:Joint consideration of well-characterized clinical characteristics with germline genetic variation and somatic mutations can enable chronic lymphocytic leukemia risk stratification to support clinical decision-making and early detection.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Both acquired mutations and germline genetic variation are known risk factors for chronic lymphocytic leukemia (CLL). The joint characterization of germline, acquired, and clinical risk has the potential to improve CLL risk prediction. In this study, we investigated whether the inclusion of a CLL-associated polygenic score (PGS) and two common types of clonal hematopoiesis (CH), autosomal mosaic chromosomal alterations (mCA) and CH of indeterminate potential (CHIP), could improve CLL risk stratification in 436,784 participants in the UK Biobank and a replication set of 35,382 participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Individual mCAs on chromosomes 11, 12, 23, 14, and 22, as well as CHIP mutations in known lymphoid driver genes, were strongly associated with CLL risk. Integrative models that included sex, age, smoking status, blood cell traits, genetic similarity, CLL PGS, autosomal mCAs, and CHIP had the greatest discriminative ability, with predictive utility waning 5 years after the measurement of CH. Sensitivity analyses removing individuals with abnormal blood cell counts and CH commonly observed in CLL showed persistent, increased discriminative ability. Evaluating cumulative absolute risk, the CLL PGS and CH had improved ability to stratify CLL cases into higher-risk categories and controls into lower-risk categories. Overall, this analysis details the enhanced ability to identify individuals at high risk of CLL when integrating germline and somatic data derived from peripheral blood.Significance:Joint consideration of well-characterized clinical characteristics with germline genetic variation and somatic mutations can enable chronic lymphocytic leukemia risk stratification to support clinical decision-making and early detection.
- Open Access
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
CLL risk estimates over time for autosomal mCA status in pooled UKBB and PLCO populations. Analyses are adjusted for age, age-squared, sex, smoking status (N/F/C), genetic similarity, CLL PGS, and study cohort. Detailed results are given in Supplemental Table 17.
- 15 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
CLL risk estimates over time for autosomal mCA status in pooled UKBB and PLCO populations. Analyses are adjusted for age, age-squared, sex, smoking status (N/F/C), genetic similarity, CLL PGS, and study cohort. Detailed results are given in Supplemental Table 17.
- 30 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (14) , 2743-2752
Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Both acquired mutations and germline genetic variation are known risk factors for chronic lymphocytic leukemia (CLL). The joint characterization of germline, acquired, and clinical risk has the potential to improve CLL risk prediction. In this study, we investigated whether the inclusion of a CLL-associated polygenic score (PGS) and two common types of clonal hematopoiesis (CH), autosomal mosaic chromosomal alterations (mCA) and CH of indeterminate potential (CHIP), could improve CLL risk stratification in 436,784 participants in the UK Biobank and a replication set of 35,382 participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Individual mCAs on chromosomes 11, 12, 23, 14, and 22, as well as CHIP mutations in known lymphoid driver genes, were strongly associated with CLL risk. Integrative models that included sex, age, smoking status, blood cell traits, genetic similarity, CLL PGS, autosomal mCAs, and CHIP had the greatest discriminative ability, with predictive utility waning 5 years after the measurement of CH. Sensitivity analyses removing individuals with abnormal blood cell counts and CH commonly observed in CLL showed persistent, increased discriminative ability. Evaluating cumulative absolute risk, the CLL PGS and CH had improved ability to stratify CLL cases into higher-risk categories and controls into lower-risk categories. Overall, this analysis details the enhanced ability to identify individuals at high risk of CLL when integrating germline and somatic data derived from peripheral blood. Significance: Joint consideration of well-characterized clinical characteristics with germline genetic variation and somatic mutations can enable chronic lymphocytic leukemia risk stratification to support clinical decision-making and early detection.
- 30 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (14) , 2743-2752
Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
Both acquired mutations and germline genetic variation are known risk factors for chronic lymphocytic leukemia (CLL). The joint characterization of germline, acquired, and clinical risk has the potential to improve CLL risk prediction. In this study, we investigated whether the inclusion of a CLL-associated polygenic score (PGS) and two common types of clonal hematopoiesis (CH), autosomal mosaic chromosomal alterations (mCA) and CH of indeterminate potential (CHIP), could improve CLL risk stratification in 436,784 participants in the UK Biobank and a replication set of 35,382 participants in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Individual mCAs on chromosomes 11, 12, 23, 14, and 22, as well as CHIP mutations in known lymphoid driver genes, were strongly associated with CLL risk. Integrative models that included sex, age, smoking status, blood cell traits, genetic similarity, CLL PGS, autosomal mCAs, and CHIP had the greatest discriminative ability, with predictive utility waning 5 years after the measurement of CH. Sensitivity analyses removing individuals with abnormal blood cell counts and CH commonly observed in CLL showed persistent, increased discriminative ability. Evaluating cumulative absolute risk, the CLL PGS and CH had improved ability to stratify CLL cases into higher-risk categories and controls into lower-risk categories. Overall, this analysis details the enhanced ability to identify individuals at high risk of CLL when integrating germline and somatic data derived from peripheral blood. Significance: Joint consideration of well-characterized clinical characteristics with germline genetic variation and somatic mutations can enable chronic lymphocytic leukemia risk stratification to support clinical decision-making and early detection.